Analysis of trametinib medical insurance reimbursement ratio and policy differences in different regions

Trametinib (Trametinib) is an oral MEK inhibitor, mainly used for patients with BRAF V600 mutation-positive melanoma and some non-small cell lung cancer. With its domestic launch, trametinib has been included in the medical insurance catalog, which provides patients with certain financial support and enables more patients to afford treatment. However, medical insurance policies and reimbursement ratios vary in different regions, and the actual payment amount may vary.

In China, trametinib is available in two specifications: 0.5mg30 tablets and 2mg30 tablets. The latest price of 0.5mg is about three to four thousand yuan, and the price of 2mg is more than nine thousand to more than ten thousand yuan. After patients are reimbursed through medical insurance, they can enjoy a certain percentage of cost reduction, but the specific reimbursement amount will vary according to local medical insurance policies, hospital purchase prices and personal medical insurance types, and needs to be verified at the pharmacy of the hospital where they are treated.

In addition, trametinib is also available in foreign markets. The price of the original version in Türkiye is about 7,000 to 8,000 yuan per box, while the price of the generic drug approved by the Lao Ministry of Health is about more than 1,000 yuan, and the ingredients are basically the same as the original version. For patients who want to obtain drugs through formal overseas channels, generic drugs provide a more economical option, but they need to pay attention to the formal source and safety of the drugs.

In short, trametinib can reduce patients' financial burden when covered by domestic medical insurance. However, due to differences in local policies, patients should learn more about the medical insurance reimbursement ratio, process and co-pay amount in their region before purchasing the drug and reimbursement. At the same time, the appropriate specifications and channels should be selected based on the doctor’s recommendations to ensure the continuity and safety of treatment.

Reference materials:https://www.drugs.com/